InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Immunome Inc.

IMNM Clue Score30
United States Fiscal year ends December CIK 0001472012
$19.55 +1.24% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $19.55 +11.71% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 2 Oct 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Operating income−10.3Net income−10.4Fiscal year 2020Operating income−12.3Net income−17.8EPS, diluted−5.26Fiscal year 2021Operating income−25.2Net income−24.7EPS, diluted−2.14Fiscal year 2022Operating income−36.9Net income−36.9EPS, diluted−3.09Fiscal year 2023Revenue14.0Operating income−109.5Net income−106.8EPS, diluted−5.38Fiscal year 2024Revenue9.0 −35.5%Operating income−305.8Net income−293.0EPS, diluted−5.00Fiscal year 2025Revenue6.9 −23.2%Operating income−224.1Net income−212.4EPS, diluted−2.43
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a 14.0 9.0 6.9
Growth −35.5% −23.2%
Operating income −10.3 −12.3 −25.2 −36.9 −109.5 −305.8 −224.1
Net income −10.4 −17.8 −24.7 −36.9 −106.8 −293.0 −212.4
Growth
EPS, diluted n/a −5.26 −2.14 −3.09 −5.38 −5.00 −2.43

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Operating margin−781.4%Net margin−761.9%Free cash flow margin−59.9%Fiscal year 2024Operating margin−3,382.4%Net margin−3,240.4%Free cash flow margin−1,304.8%Fiscal year 2025Operating margin−3,228.8%Net margin−3,060.0%Free cash flow margin−2,890.1%
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −781.4% −3,382.4% −3,228.8%
Net margin n/a n/a n/a n/a −761.9% −3,240.4% −3,060.0%
Free cash flow margin n/a n/a n/a n/a −59.9% −1,304.8% −2,890.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−9.6Capital expenditure−0.2Free cash flow−9.8Fiscal year 2020Operating cash flow−12.1Capital expenditure−0.6Free cash flow−12.7Fiscal year 2021Operating cash flow−18.2Capital expenditure−0.1Free cash flow−18.3Fiscal year 2022Operating cash flow−28.7Capital expenditure−0.2Free cash flow−28.9Fiscal year 2023Operating cash flow−7.6Capital expenditure−0.8Free cash flow−8.4Fiscal year 2024Operating cash flow−110.8Capital expenditure−7.2Free cash flow−118.0Fiscal year 2025Operating cash flow−190.9Capital expenditure−9.7Free cash flow−200.6
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −9.6 −12.1 −18.2 −28.7 −7.6 −110.8 −190.9
Capital expenditure −0.2 −0.6 −0.1 −0.2 −0.8 −7.2 −9.7
Free cash flow −9.8 −12.7 −18.3 −28.9 −8.4 −118.0 −200.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash2.5Shareholders’ equity−35.6Fiscal year 2020Cash39.8Total debt0.5Net cash (debt)39.3Shareholders’ equity41.3Debt to equity0.01Fiscal year 2021Cash49.2Shareholders’ equity48.2Fiscal year 2022Cash20.3Shareholders’ equity16.7Fiscal year 2023Cash98.7Shareholders’ equity119.9Fiscal year 2024Cash143.4Shareholders’ equity181.2Fiscal year 2025Cash653.5Shareholders’ equity634.3
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 2.5 39.8 49.2 20.3 98.7 143.4 653.5
Total debt n/a 0.5 n/a n/a n/a n/a n/a
Net cash (debt) n/a 39.3 n/a n/a n/a n/a n/a
Shareholders’ equity −35.6 41.3 48.2 16.7 119.9 181.2 634.3
Debt to equity n/a 0.01 n/a n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a n/a 14.0 9.0 6.9
Growth −35.5% −23.2%
8.8 7.5 14.1 23.3 23.1 129.5 177.3
1.5 4.8 11.1 13.6 19.7 33.0 43.8
−10.3 −12.3 −25.2 −36.9 −109.5 −305.8 −224.1
Growth
0.0 0.0 0.0 0.0 0.0 0.0 0.0
−10.4 −17.8 −24.7 −36.9 −106.8 −293.0 −212.4
Growth
Per share
n/a −5.26 −2.14 −3.09 −5.38 −5.00 −2.43
n/a −5.26 −2.14 −3.09 −5.38 −5.00 −2.43
Growth
n/a 3.4 11.5 12.1 19.8 58.6 87.4
n/a 3.4 11.5 12.1 19.8 58.6 87.4
Growth +240.4% +5.1% +63.6% +195.5% +49.0%

† The diluted share count jumps at 2021 and 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 7 of 7 years on file.